Reducing Tumour Hypoxia via Oral Administration of Oxygen Nanobubbles

Joshua Owen, Conor McEwan, Heather Nesbitt, Phurit Bovornchutichai, Raymond Averre, Mark Borden, Anthony McHale, John F Callan, Eelanor Stride

Research output: Contribution to journalArticlepeer-review

47 Citations (Scopus)
42 Downloads (Pure)


Hypoxia has been shown to be a key factor inhibiting the successful treatment of solid tumours. Existing strategies for reducing hypoxia, however, have shown limited efficacy and/or adverse side effects. The aim of this study was to investigate the potential for reducing tumour hypoxia using an orally delivered suspension of surfactant-stabilised oxygen nanobubbles. Experiments were carried out in a mouse xenograft tumour model for human pancreatic cancer (BxPc-3 cells in male SCID mice). A single dose of 100 μL of oxygen saturated water, oxygen nanobubbles or argon nanobubbles was administered via gavage. Animals were sacrificed 30 minutes post-treatment (3 per group) and expression of hypoxiainducible-factor-1α (HIF1α) protein measured by real time quantitative polymerase chain reaction and Western blot analysis of the excised tumour tissue. Neither the oxygen saturated water nor argon nanobubbles produced a statistically significant change in HIF1α expression at the transcriptional level. In contrast, a reduction of 75% and 25% in the transcriptional and translational expression of HIF1α respectively (p
Original languageEnglish
Pages (from-to)e0168088
JournalPLoS ONE
Issue number12
Publication statusPublished (in print/issue) - 30 Dec 2016


  • Nanobubbles
  • Oxygen
  • Hypoxia
  • HIF-1 alpha


Dive into the research topics of 'Reducing Tumour Hypoxia via Oral Administration of Oxygen Nanobubbles'. Together they form a unique fingerprint.

Cite this